A detailed history of Anderson Hoagland & CO transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Anderson Hoagland & CO holds 3,389 shares of REGN stock, worth $2.42 Million. This represents 0.37% of its overall portfolio holdings.

Number of Shares
3,389
Previous 3,489 2.87%
Holding current value
$2.42 Million
Previous $3.67 Million 2.86%
% of portfolio
0.37%
Previous 0.4%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 07, 2024

SELL
$1024.09 - $1201.76 $102,408 - $120,176
-100 Reduced 2.87%
3,389 $3.56 Million
Q1 2024

Apr 11, 2024

SELL
$902.69 - $993.35 $1.41 Million - $1.56 Million
-1,566 Reduced 30.98%
3,489 $3.36 Million
Q4 2023

Jan 17, 2024

SELL
$775.18 - $881.7 $42,634 - $48,493
-55 Reduced 1.08%
5,055 $4.44 Million
Q3 2023

Oct 10, 2023

BUY
$692.45 - $844.37 $1,384 - $1,688
2 Added 0.04%
5,110 $4.21 Million
Q4 2022

Jan 20, 2023

BUY
$705.89 - $766.39 $415,063 - $450,637
588 Added 13.01%
5,108 $0
Q3 2022

Oct 11, 2022

BUY
$573.97 - $724.32 $9,183 - $11,589
16 Added 0.36%
4,520 $3.11 Million
Q4 2021

Jan 25, 2022

BUY
$543.48 - $670.97 $48,369 - $59,716
89 Added 2.02%
4,504 $2.8 Million
Q3 2021

Oct 07, 2021

BUY
$574.03 - $680.96 $2.53 Million - $3.01 Million
4,415 New
4,415 $2.67 Million
Q1 2021

Apr 09, 2021

SELL
$446.73 - $548.2 $1.17 Million - $1.44 Million
-2,624 Closed
0 $0
Q4 2020

Feb 03, 2021

BUY
$478.3 - $607.98 $513,694 - $652,970
1,074 Added 69.29%
2,624 $1.27 Million
Q3 2020

Oct 06, 2020

SELL
$544.75 - $658.21 $27,237 - $32,910
-50 Reduced 3.13%
1,550 $967,000
Q2 2020

Jul 06, 2020

BUY
$493.32 - $643.92 $789,312 - $1.03 Million
1,600 New
1,600 $998,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $76.6B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Anderson Hoagland & CO Portfolio

Follow Anderson Hoagland & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Anderson Hoagland & CO, based on Form 13F filings with the SEC.

News

Stay updated on Anderson Hoagland & CO with notifications on news.